| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2012-09-06 21:03:48 UTC |
|---|
| Update Date | 2021-09-14 15:45:02 UTC |
|---|
| HMDB ID | HMDB0029130 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Valylisoleucine |
|---|
| Description | Valylisoleucine is a dipeptide composed of valine and isoleucine. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. |
|---|
| Structure | CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O InChI=1S/C11H22N2O3/c1-5-7(4)9(11(15)16)13-10(14)8(12)6(2)3/h6-9H,5,12H2,1-4H3,(H,13,14)(H,15,16)/t7-,8-,9-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| L-Val-L-ile | ChEBI | | Valyl-isoleucine | ChEBI | | VI | ChEBI | | L-Valyl-L-isoleucine | HMDB | | N-L-Valyl-L-isoleucine | HMDB | | N-Valylisoleucine | HMDB | | V-I dipeptide | HMDB | | VI dipeptide | HMDB | | Val-ile | HMDB | | Valine isoleucine dipeptide | HMDB | | Valine-isoleucine dipeptide | HMDB | | Valylisoleucine | ChEBI |
|
|---|
| Chemical Formula | C11H22N2O3 |
|---|
| Average Molecular Weight | 230.308 |
|---|
| Monoisotopic Molecular Weight | 230.163042576 |
|---|
| IUPAC Name | (2S,3S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylpentanoic acid |
|---|
| Traditional Name | (2S,3S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylpentanoic acid |
|---|
| CAS Registry Number | 20556-14-3 |
|---|
| SMILES | CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O |
|---|
| InChI Identifier | InChI=1S/C11H22N2O3/c1-5-7(4)9(11(15)16)13-10(14)8(12)6(2)3/h6-9H,5,12H2,1-4H3,(H,13,14)(H,15,16)/t7-,8-,9-/m0/s1 |
|---|
| InChI Key | PNVLWFYAPWAQMU-CIUDSAMLSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | Dipeptides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Alpha-dipeptide
- Isoleucine or derivatives
- Valine or derivatives
- N-acyl-alpha-amino acid
- N-acyl-l-alpha-amino acid
- N-acyl-alpha amino acid or derivatives
- Alpha-amino acid amide
- Alpha-amino acid or derivatives
- Branched fatty acid
- Methyl-branched fatty acid
- Fatty amide
- N-acyl-amine
- Fatty acyl
- Fatty acid
- Amino acid or derivatives
- Carboxamide group
- Carboxylic acid salt
- Amino acid
- Secondary carboxylic acid amide
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Organic salt
- Hydrocarbon derivative
- Amine
- Primary aliphatic amine
- Organic oxide
- Organic oxygen compound
- Organic nitrogen compound
- Carbonyl group
- Organopnictogen compound
- Organonitrogen compound
- Organooxygen compound
- Primary amine
- Organic zwitterion
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | -1.16 | Extrapolated |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross Sections| Predictor | Adduct Type | CCS Value (Å2) | Reference |
|---|
| DeepCCS | [M+H]+ | 163.819 | 30932474 | | DeepCCS | [M-H]- | 161.424 | 30932474 | | DeepCCS | [M-2H]- | 194.308 | 30932474 | | DeepCCS | [M+Na]+ | 169.732 | 30932474 |
Predicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.18 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.8166 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 6.18 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 181.0 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1268.2 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 219.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 101.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 153.1 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 67.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 322.8 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 356.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 168.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 710.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 335.6 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1012.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 183.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 242.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 306.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 342.8 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 100.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Valylisoleucine,1TMS,isomer #1 | CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)O[Si](C)(C)C | 1797.7 | Semi standard non polar | 33892256 | | Valylisoleucine,1TMS,isomer #2 | CC[C@H](C)[C@H](NC(=O)[C@@H](N[Si](C)(C)C)C(C)C)C(=O)O | 1831.3 | Semi standard non polar | 33892256 | | Valylisoleucine,1TMS,isomer #3 | CC[C@H](C)[C@@H](C(=O)O)N(C(=O)[C@@H](N)C(C)C)[Si](C)(C)C | 1778.8 | Semi standard non polar | 33892256 | | Valylisoleucine,2TMS,isomer #1 | CC[C@H](C)[C@H](NC(=O)[C@@H](N[Si](C)(C)C)C(C)C)C(=O)O[Si](C)(C)C | 1878.9 | Semi standard non polar | 33892256 | | Valylisoleucine,2TMS,isomer #1 | CC[C@H](C)[C@H](NC(=O)[C@@H](N[Si](C)(C)C)C(C)C)C(=O)O[Si](C)(C)C | 1846.8 | Standard non polar | 33892256 | | Valylisoleucine,2TMS,isomer #2 | CC[C@H](C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@@H](N)C(C)C)[Si](C)(C)C | 1791.2 | Semi standard non polar | 33892256 | | Valylisoleucine,2TMS,isomer #2 | CC[C@H](C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@@H](N)C(C)C)[Si](C)(C)C | 1887.2 | Standard non polar | 33892256 | | Valylisoleucine,2TMS,isomer #3 | CC[C@H](C)[C@@H](C(=O)O)N(C(=O)[C@@H](N[Si](C)(C)C)C(C)C)[Si](C)(C)C | 1826.6 | Semi standard non polar | 33892256 | | Valylisoleucine,2TMS,isomer #3 | CC[C@H](C)[C@@H](C(=O)O)N(C(=O)[C@@H](N[Si](C)(C)C)C(C)C)[Si](C)(C)C | 1851.5 | Standard non polar | 33892256 | | Valylisoleucine,2TMS,isomer #4 | CC[C@H](C)[C@H](NC(=O)[C@H](C(C)C)N([Si](C)(C)C)[Si](C)(C)C)C(=O)O | 1989.3 | Semi standard non polar | 33892256 | | Valylisoleucine,2TMS,isomer #4 | CC[C@H](C)[C@H](NC(=O)[C@H](C(C)C)N([Si](C)(C)C)[Si](C)(C)C)C(=O)O | 1882.3 | Standard non polar | 33892256 | | Valylisoleucine,3TMS,isomer #1 | CC[C@H](C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@@H](N[Si](C)(C)C)C(C)C)[Si](C)(C)C | 1860.0 | Semi standard non polar | 33892256 | | Valylisoleucine,3TMS,isomer #1 | CC[C@H](C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@@H](N[Si](C)(C)C)C(C)C)[Si](C)(C)C | 1910.7 | Standard non polar | 33892256 | | Valylisoleucine,3TMS,isomer #2 | CC[C@H](C)[C@H](NC(=O)[C@H](C(C)C)N([Si](C)(C)C)[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2001.5 | Semi standard non polar | 33892256 | | Valylisoleucine,3TMS,isomer #2 | CC[C@H](C)[C@H](NC(=O)[C@H](C(C)C)N([Si](C)(C)C)[Si](C)(C)C)C(=O)O[Si](C)(C)C | 1983.8 | Standard non polar | 33892256 | | Valylisoleucine,3TMS,isomer #3 | CC[C@H](C)[C@@H](C(=O)O)N(C(=O)[C@H](C(C)C)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 1981.5 | Semi standard non polar | 33892256 | | Valylisoleucine,3TMS,isomer #3 | CC[C@H](C)[C@@H](C(=O)O)N(C(=O)[C@H](C(C)C)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 1999.3 | Standard non polar | 33892256 | | Valylisoleucine,4TMS,isomer #1 | CC[C@H](C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@H](C(C)C)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 2045.0 | Semi standard non polar | 33892256 | | Valylisoleucine,4TMS,isomer #1 | CC[C@H](C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@H](C(C)C)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 2070.8 | Standard non polar | 33892256 | | Valylisoleucine,1TBDMS,isomer #1 | CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2030.6 | Semi standard non polar | 33892256 | | Valylisoleucine,1TBDMS,isomer #2 | CC[C@H](C)[C@H](NC(=O)[C@@H](N[Si](C)(C)C(C)(C)C)C(C)C)C(=O)O | 2056.1 | Semi standard non polar | 33892256 | | Valylisoleucine,1TBDMS,isomer #3 | CC[C@H](C)[C@@H](C(=O)O)N(C(=O)[C@@H](N)C(C)C)[Si](C)(C)C(C)(C)C | 1997.7 | Semi standard non polar | 33892256 | | Valylisoleucine,2TBDMS,isomer #1 | CC[C@H](C)[C@H](NC(=O)[C@@H](N[Si](C)(C)C(C)(C)C)C(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2299.8 | Semi standard non polar | 33892256 | | Valylisoleucine,2TBDMS,isomer #1 | CC[C@H](C)[C@H](NC(=O)[C@@H](N[Si](C)(C)C(C)(C)C)C(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2235.3 | Standard non polar | 33892256 | | Valylisoleucine,2TBDMS,isomer #2 | CC[C@H](C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@@H](N)C(C)C)[Si](C)(C)C(C)(C)C | 2239.6 | Semi standard non polar | 33892256 | | Valylisoleucine,2TBDMS,isomer #2 | CC[C@H](C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@@H](N)C(C)C)[Si](C)(C)C(C)(C)C | 2285.5 | Standard non polar | 33892256 | | Valylisoleucine,2TBDMS,isomer #3 | CC[C@H](C)[C@@H](C(=O)O)N(C(=O)[C@@H](N[Si](C)(C)C(C)(C)C)C(C)C)[Si](C)(C)C(C)(C)C | 2282.0 | Semi standard non polar | 33892256 | | Valylisoleucine,2TBDMS,isomer #3 | CC[C@H](C)[C@@H](C(=O)O)N(C(=O)[C@@H](N[Si](C)(C)C(C)(C)C)C(C)C)[Si](C)(C)C(C)(C)C | 2216.7 | Standard non polar | 33892256 | | Valylisoleucine,2TBDMS,isomer #4 | CC[C@H](C)[C@H](NC(=O)[C@H](C(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O | 2429.2 | Semi standard non polar | 33892256 | | Valylisoleucine,2TBDMS,isomer #4 | CC[C@H](C)[C@H](NC(=O)[C@H](C(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O | 2250.5 | Standard non polar | 33892256 | | Valylisoleucine,3TBDMS,isomer #1 | CC[C@H](C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@@H](N[Si](C)(C)C(C)(C)C)C(C)C)[Si](C)(C)C(C)(C)C | 2511.5 | Semi standard non polar | 33892256 | | Valylisoleucine,3TBDMS,isomer #1 | CC[C@H](C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@@H](N[Si](C)(C)C(C)(C)C)C(C)C)[Si](C)(C)C(C)(C)C | 2470.7 | Standard non polar | 33892256 | | Valylisoleucine,3TBDMS,isomer #2 | CC[C@H](C)[C@H](NC(=O)[C@H](C(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2665.6 | Semi standard non polar | 33892256 | | Valylisoleucine,3TBDMS,isomer #2 | CC[C@H](C)[C@H](NC(=O)[C@H](C(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2512.8 | Standard non polar | 33892256 | | Valylisoleucine,3TBDMS,isomer #3 | CC[C@H](C)[C@@H](C(=O)O)N(C(=O)[C@H](C(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2638.9 | Semi standard non polar | 33892256 | | Valylisoleucine,3TBDMS,isomer #3 | CC[C@H](C)[C@@H](C(=O)O)N(C(=O)[C@H](C(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2520.5 | Standard non polar | 33892256 | | Valylisoleucine,4TBDMS,isomer #1 | CC[C@H](C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@H](C(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2918.5 | Semi standard non polar | 33892256 | | Valylisoleucine,4TBDMS,isomer #1 | CC[C@H](C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@H](C(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2766.8 | Standard non polar | 33892256 |
|
|---|
| Disease References | | Colorectal cancer |
|---|
- Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
- Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
|
|
|---|